MBX Biosciences third quarter 2026 loss widened to $62.4M amid Phase 3 trial initiation

MBX Biosciences reported a net loss of $62.4 million for the third quarter 2026, driven by the commencement of its pivotal Phase 3 oPTimize trial and a one-time $20.8 million stock-based compensation charge. The company remains pre-revenue but maintains a strong liquidity position of $481.6 million to fund clinical milestones into 2029.

Key Highlights

• Dosing of the first patient in the pivotal Phase 3 oPTimize trial of canvuparatide (PTH replacement therapy) was completed in August 2026.
• Cash and marketable securities of $481.6 million include $97.6 million in net proceeds from recent at-the-market (ATM) stock sales.
• Research and development expenses increased to $32.0 million from $19.3 million year-over-year due to heightened Phase 3 start-up costs and ongoing Phase 1 obesity trials.